Canaccord Genuity Downgrades GreenLight Biosciences to Hold, Lowers Price Target to $0.3
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Bobby Burleson downgrades GreenLight Biosciences (NASDAQ:GRNA) from Buy to Hold and lowers the price target from $4 to $0.3.
May 31, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Canaccord Genuity downgraded GreenLight Biosciences (GRNA) to Hold and lowered the price target from $4 to $0.3.
The downgrade from Buy to Hold and the significant reduction in the price target from $4 to $0.3 by Canaccord Genuity analyst Bobby Burleson indicate a negative outlook for GreenLight Biosciences. This could lead to a short-term decline in the stock price as investors may lose confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100